Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adaptive Radiotherapy for Stage II-III Non-small Cell Lung Cancer

NCT01207063 is registered in ClinicalTrials.gov with Maastricht Radiation Oncology as lead sponsor.

NCT NCT01207063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01207063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adaptive Radiotherapy for Stage II-III Non-small Cell Lung Cancer
Lead sponsor
Maastricht Radiation Oncology
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2011
Completion date
August 31, 2018
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer